CryositeASX:CTE +8.49%51 EBITDA Margin % is 23.38% as of Dec. 2025, which is 31% above its 10-year median of 17.86. GuruFocus rates ASX:CTE with a GF Score™ of 51/100 and a GF Value™ of A$0.94 (Modestly Overvalued). Among 204 Medical Diagnostics & Research companies, Cryosite ranks better than 79.9% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cryosite's EBITDA for the
six
months ended in Dec. 2025 was A$1.93 Mil. Cryosite's Revenue for the
six
months ended in Dec. 2025 was A$8.27 Mil. Therefore, Cryosite's EBITDA margin for the quarter that ended in Dec. 2025 was 23.38%.
Cryosite (ASX:CTE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cryosite EBITDA Margin % Related Terms
Cryosite EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cryosite's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CTE vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Cryosite's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryosite EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cryosite's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryosite (ASX:CTE) has a EBITDA Margin % of 23.38% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cryosite and its competitors. This is 31% above median its historical median of 17.86. According to the industry distribution chart, Cryosite ranks #41 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 20.1%.
Is Cryosite's EBITDA Margin % too high?
Cryosite's current EBITDA Margin % of 23.38% is 31% above median its 10-year median of 17.86. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Cryosite's value of 23.38% is 349.6% above this industry median. Based on the distribution chart, Cryosite ranks #41 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cryosite has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cryosite ranks #41 out of 204 companies for EBITDA Margin %. This places Cryosite in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. Cryosite's value of 23.38% is 349.6% above this benchmark. While the company's 10-year median is 17.86 vs. the industry median of 5.20, Cryosite has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryosite's current EBITDA Margin % of 23.38% is 349.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cryosite and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryosite's current EBITDA Margin % is 23.38%, which is 31% above median its own 10-year median of 17.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.94, compared to a current price of A$1.15 — trading 22.3% above its estimated fair value. The current EBITDA Margin % is 23.38%, which is 31% above median its 10-year median of 17.86 and 349.6% above the Medical Diagnostics & Research industry median of 5.20. Cryosite's overall GF Score™ is 51/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current EBITDA Margin % is 23.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryosite (ASX:CTE) Overvalued in 2026?
Based on GuruFocus' analysis, Cryosite stock appears to be overvalued.
The current stock price of A$1.15 is trading 22.3% above its estimated GF Value™ of A$0.94.
GuruFocus considers Cryosite to be Modestly Overvalued.
Key valuation signals for ASX:CTE:
EBITDA Margin %: 23.38% (31% above median its 10-year median of 17.86)
GF Value™: A$0.94 vs. price of A$1.15 (22.3% above fair value)
Industry Position: 349.6% above the Medical Diagnostics & Research median (#41 of 204)
No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score
Get the complete analysis for ASX:CTE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTE has been successfully added to your 
